Regenxbio Inc.
RGNXCIK 0001590877 · last filing Jul 6, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
40,339 bought / 65,312 sold
net −24,973 sh · −$487.0K
- buys
- 3
- sells
- 4
- insiders active
- 2
Filing tape
Filed Mon, Jul 6, 2026
- −0 sh · $12.5K
Pakola Steve — Chief Medical Officer
- Exercised2,161Common Stock@ $7.86→ 215,170 held
- Sold2,161Common Stock@ $13.64→ 213,009 held
- Exercised2,161Stock Options (Right to Buy)→ 64,812 held
- −4,414 sh · $67.8K
Simpson Curran — Chief Executive Officer · Director
- Granted951Common Stock@ $7.00→ 343,418 heldtrade dated Dec 31, 2025
- Granted1,453Common Stock@ $10.18→ 344,871 held
- Withheld for tax6,818Common Stock@ $13.09→ 338,053 held
Filed Wed, Jul 1, 2026
- −19,608 sh · $400.1K
Pakola Steve — Chief Medical Officer
- Sold19,608Common Stock@ $11.04→ 213,009 held
- Exercised36,725Common Stock@ $7.86→ 249,734 held
- Sold36,725Common Stock@ $12.86→ 213,009 held
- Exercised36,725Stock Options (Right to Buy)→ 66,973 held
Insiders on this tape
- Pakola SteveChief Medical Officer
- Simpson CurranChief Executive Officer · Director
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.